Home Tags Biotechnology

Tag: biotechnology

Exelixis and Catalent to Jointly Develop Multiple SMARTag®-based Antibody-drug Conjugates

Alameda- (California-) based Exelixis confirmed that it has signed a partnership agreement with Catalent to develop multiple antibody-drug conjugates (ADCs) using Catalent's proprietary SMARTag®...

CPhI Worldwide Attendees Expect Global Pharma Economies to Rapidly Grow

Set against the backdrop of one of the most important business centers in Madrid, Spain, the IFEMA Feria de Madrid hosted this year's 29th...

Synaffix Secures End-to-end Patent Protection for GlycoConnect Technology

The Netherlands-based Synaffix, a biotechnology company that has developed a proprietary site-specific platform technology to enable differentiated antibody-drug conjugates (ADCs), has received a key...

Sorrento Therapeutics Completes Manufacturing Facility in China

Earlier today Sorrento Therapeutics announced that its subsidiary, Levena Biopharma, completed construction of its new, 25,000 sq/ft GMP manufacturing facility in Suzhou, China.  The facility...

Synaffix’s New High Potency Lab now Fully Operational to Support Growing...

Late last week, Synaffix, a Dutch biotechnology company backed by a top tier, life science-focused, investor syndicate and the strategic corporate venture capital fund of...

Lonza Expands it’s Mammalian Production Capacity

Over the last decade, biologics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), therapeutic proteins, immunotherapeutics, and therapeutic (cancer) vaccines have greatly transformed treatment of...

Scientists Tweak proteins with ‘Tub-tag’

Scientists from Ludwig-Maximilians-Universitaet (LMU) in Munich, Germany, together with colleagues based in Berlin, have developed a rapid and efficient technique for targeted chemoenzymatic functionalization of...
BT-062-Multiple-Myeloma-BIOTEST

Report Presents Latest Development in CMO Market for ADCs

While the basic concept of Antibody-drug Conjugates (ADCs), a new class of biopharmaceutical drugs designed as a targeted therapy, is quite simple - a biological active cytotoxic or chemotherapy drug, is delivered to the target tissue through linking it with a monoclonal antibody - the practical challenge of manufacturing such complex and highly toxic molecules is huge.